RegistRare: a Retro-prospective Registry of Rare Primary Headaches in Italian Tertiary Headache Centres
Launched by SILVIA BENEMEI · Jan 23, 2018
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The RegistRare trial is studying rare types of primary headaches, which are specific kinds of headaches that don’t occur because of another medical condition. This research is taking place in several specialized headache centers across Italy and is looking at how common these rare headaches are among patients over a three-year period. The study will collect information from patients who have already been diagnosed with these headaches (from May 2014 to April 2017) and will continue to gather new data each year after that.
If you or a loved one has been diagnosed with a rare primary headache and are interested in participating, you may be eligible to join this study. The main requirement is that you must have a confirmed diagnosis of one of these rare headaches and be willing to sign a consent form to participate. There are no specific exclusions, so almost anyone who meets the diagnosis criteria can join. Participants can expect to share their medical history and information about their headaches, which will help researchers better understand these conditions and improve care for others in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • diagnosis of rare primary headaches (Part One, Chapter 3 and Chapter 4, ICHD-3 beta)
- • signed informed consent
- Exclusion Criteria:
- • none
About Silvia Benemei
Silvia Benemei is a dedicated clinical trial sponsor committed to advancing medical research and improving patient outcomes through innovative studies. With a focus on precision medicine and patient-centric approaches, the organization collaborates with leading healthcare institutions and researchers to develop and implement rigorous clinical trials. By prioritizing ethical practices and robust methodologies, Silvia Benemei aims to contribute valuable insights to the scientific community and facilitate the development of new therapies that address unmet medical needs. The sponsor is driven by a mission to enhance the quality of life for patients through evidence-based interventions and comprehensive care solutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Florence, , Italy
Patients applied
Trial Officials
Silvia Benemei, MD
Study Chair
Careggi University Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials